# EDGAR Filing Document

**Accession Number:** 0001489798
**File Stem:** 0001213900-25-115725
**Filing Date:** 2025-11
**Character Count:** 7109
**Document Hash:** 8e43e365fd36d7aab8a9da8068c2fd1b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-115725.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001213900-25-115725

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251124

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Dillione Janet
- **CENTRAL INDEX KEY:** 0001489798

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34673
- **FILM NUMBER:** 251532152

**MAIL ADDRESS:**
- **STREET 1:** ONE WAYSIDE ROAD
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CorMedix Inc.
- **CENTRAL INDEX KEY:** 0001410098
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 300 CONNELL DRIVE
- **STREET 2:** SUITE 4200
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922
- **BUSINESS PHONE:** 908-517-9500

**MAIL ADDRESS:**
- **STREET 1:** 300 CONNELL DRIVE
- **STREET 2:** SUITE 4200
- **CITY:** BERKELEY HEIGHTS
- **STATE:** NJ
- **ZIP:** 07922

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Dillione Janet<br><sub>(Last) (First) (Middle)</sub><br>C/O CORMEDIX INC.,<br>300 CONNELL DRIVE, SUITE 4200<br><sub>(Street)</sub><br>BERKELEY HEIGHTS, NJ 07922<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-24 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CorMedix Inc. [ CRMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-24 |  | M |  | 8000 | A | $2.85 | 56473 | D |  |
| Common Stock | 2025-11-24 |  | M |  | 7790 | A | $4.03 | 64263 | D |  |
| Common Stock | 2025-11-24 |  | M |  | 4876 | A | $4.43 | 69139 | D |  |
| Common Stock | 2025-11-24 |  | M |  | 5677 | A | $3.55 | 74816 | D |  |
| Common Stock | 2025-11-24 |  | S |  | 26343 | D | 9.93<sup>(1)</sup> | 48473 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy Common Stock) | $2.85 | 2025-11-24 |  | M |  |  | 8000 | <sup>(2)</sup> | 2028-02-16 | Common Stock | 8000 | $0 | 0 | D |  |
| Stock Option (Right to Buy Common Stock) | $4.03 | 2025-11-24 |  | M |  |  | 7790 | <sup>(3)</sup> | 2032-02-22 | Common Stock | 7790 | $0 | 12210 | D |  |
| Stock Option (Right to Buy Common Stock) | $4.43 | 2025-11-24 |  | M |  |  | 4876 | <sup>(4)</sup> | 2033-01-14 | Common Stock | 4876 | $0 | 15124 | D |  |
| Stock Option (Right to Buy Common Stock) | $3.55 | 2025-11-24 |  | M |  |  | 5677 | <sup>(5)</sup> | 2034-03-05 | Common Stock | 5677 | $0 | 24323 | D |  |

---

### Footnotes:

(1) This transaction was executed in multiple trades at prices ranging from $9.72 to $10.00, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

(2) These options were granted on 02/16/2018. These options are fully vested.

(3) These options were granted on 02/22/2022. These options are fully vested.

(4) These options were granted on 01/14/2023. These options are fully vested.

(5) These options were granted on 03/05/2024. These options are fully vested.

**Signature:** /s/ Janet Dillione  
**Date:** 2025-11-26

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**